ADRB2-Targeting Therapies for Prostate Cancer. | Cancers (Basel);11(3)2019 Mar 13. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

ADRB2-Targeting Therapies for Prostate Cancer.

Kulik, George.

Affiliation

Kulik G; Department of Cancer Biology, Wake Forest University Health Sciences, Medical Center Blvd, Winston-Salem, NC 27157, USA. gkulik@wakehealth.edu.

Cancers (Basel) ; 11(3)2019 Mar 13.

Article in En | MEDLINE | ID: mdl-30871232

Key words

BCL-2-associated death promoter (BAD); apoptosis; cAMP-dependent protein kinase (PKA); clinical trial; myeloid cell leukemia 1 (MCL-1); propranolol; prostate cancer; ß-2 adrenergic receptor (ADRB2)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2019 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2019 Document type: Article Affiliation country: Country of publication: